Gonadotropin-releasing hormone (GnRH) analogues

Phase 1Small molecule

Gonadotropin-releasing hormone (GnRH) analogues is one of 38 small molecule programs targeting Metastatic Neuroendocrine Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Neuroendocrine Prostate CancerActive, not recruiting

Prostate CancerRecruiting

Metastatic Neuroendocrine Prostate CancerPhase 1

Active, not recruiting

Prostate CancerPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Xaluritamig

Amgen

Phase 3

4 2

Radium-223

Bayer

Phase 3

6 3

Triptorelin Embonate

Ipsen

Phase 3

3 4

Lhrha

Johnson & Johnson

Phase 3

2 5

Docetaxel /m²

AstraZeneca

Phase 3

2 6

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 7

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

2 8

Trexall

Duragesic

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Prostate Cancer

NCT06531499

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Recruiting· Novartis logo

Novartis·Phase 1·NCT06531499·106 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT06379217·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gonadotropin-releasing hormone (GnRH) analogues. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gonadotropin-releasing hormone (GnRH) analogues compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gonadotropin-releasing hormone (GnRH) analogues. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novartis

Gonadotropin-releasing hormone (GnRH) analogues

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Prostate Cancer1 trial

Metastatic Neuroendocrine Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News